While research on novel therapeutic applications of ketamine is expanding, particularly in controlled settings, there is limited exploration of its consumption related to self-treatment of psychiatric conditions. This study investigated the characteristics of people who use ketamine and psychedelics for self-treatment of psychiatric conditions, providing insight into patterns of use within this...
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used in trauma and emergency medicine for its rapid analgesic and sedative properties. While its efficacy in acute pain management is well established, concerns persist regarding its long-term psychological effects, particularly its potential role in the development of posttraumatic stress disorder (PTSD). Some studies...
Ketamine has well-known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from one another. Considering that specific cortical oscillations have been associated with specific therapeutic effects, modulating selective aspects of ketamine neurophysiology could inform...
Ketamine consists of two enantiomers, (R)-ketamine and (S)-ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)-enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)-ketamine. The quantitative electroencephalography (qEEG) gamma-enhancing effect of...
Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. The objective of this study was to test whether opioid system modulation via naltrexone alters ketamine's acute effects on regional cerebral blood flow (rCBF) in major depressive disorder (MDD), and whether these changes relate to symptom measures and map onto receptor density profiles....
Aims: To review and compare the safety, efficacy, cost-effectiveness and remission rates of electroconvulsive therapy (ECT) versus ketamine in patients with major depressive episodes. Methods: A narrative review of the literature was undertaken, focusing on randomised and non-randomised clinical trials, systematic reviews, and meta-analyses comparing ketamine and ECT in adults with major...
Les troubles liés à l’usage de substances (TUS) touchent environ 2 % de la population mondiale et sont associés à une morbidité importante ainsi qu’à un risque de rechute élevé. Les envies impérieuses (le craving), définies comme une envie intense de consommer une substance, constituent une caractéristique centrale et transdiagnostique des TUS et représentent un prédicteur clé de rechute. Les...
BJPsych OpenJune 1, 2026Imtiaz Ahmad Dogar, Palvisha Sajid, Dua Fatima et al.
Aims: In the light of limited relevant local literature, we planned our research to build a scientific database related to the immediate and sustained effects of this innovative treatment modality at our tertiary care hospital, in order to start ketamine clinic in our department . We didn’t find any research in Faisalabad, Pakistan on the subject, ensuring a more in depth understanding of the...
The Journal of PhysiologyJune 1, 2026Felipe Guiffa-Gómez, Sashá Van Buuren, Freddy Aguilar et al.1 citation
The medial prefrontal cortex (mPFC) undergoes extensive GABAergic interneuron maturation during adolescence, a process that establishes excitatory-inhibitory balance and supports adult cognitive function. Disruptions during this critical developmental period contribute to neuropsychiatric disorders, yet the enduring consequences for adult synaptic plasticity remain poorly understood. Here we...
Asian Journal of PsychiatryJune 1, 2026Hariprasad Ganapathy Vijayakumar, Varsha Shamanna, Harsh Pathak et al.1 citation
Treatment resistance in bipolar depression is one of the most challenging clinical conditions to treat in psychiatry. We present a case of an elderly gentleman with chronic Multi-Therapy Resistant Bipolar Depression (MTRBD), where ketamine, a preferential NMDAR blocker on cortical GABAergic interneurons, is used adjunctively with sequential theta burst stimulation (sTBS) to achieve remission....